Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,341 to 3,360 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| QIV-HD vs QIV-SD: Number of Participants Reporting Serious Adverse Events (SAEs) | 2 of 1,049 5 of 1,051 | -0.3 points -0.9 to 0.3 | 2,100 | NCT04498832 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older |
| QIV-HD vs QIV-SD: serious adverse events | 2 of 1,049 5 of 1,051 | -0.3 points -0.9 to 0.3 | 2,100 | NCT04498832 Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older |
| 13vPnC: Visit 1 to Visit 2 vs 13vPnC: 6-month Follow-up: serious adverse events | 10 of 1,049 41 of 1,049 | -3.0 points -4.4 to -1.7 | 2,098 | NCT00500266 Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects |
| Standard Supportive Care (SOC) vs Epoetin Alfa: serious adverse events | 229 of 1,045 251 of 1,051 | -2.0 points -5.6 to 1.6 | 2,096 | NCT00338286 A Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care Only in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Uric Acid | 124 of 1,514 48 of 579 | -0.1 points -2.9 to 2.4 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Albumin | 3 of 1,514 1 of 579 | 0.0 points -0.8 to 0.4 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Triglycerides | 329 of 1,514 101 of 579 | 4.3 points 0.4 to 7.9 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Glucose | 7 of 1,514 1 of 579 | 0.3 points -0.5 to 0.8 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Cholesterol | 1 of 1,514 1 of 579 | -0.1 points -0.9 to 0.2 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Amylase | 92 of 1,514 35 of 579 | 0.0 points -2.5 to 2.2 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Alkaline Phosphatase (AP) | 7 of 1,514 0 of 579 | 0.5 points -0.2 to 1.0 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Bilirubin | 6 of 1,514 3 of 579 | -0.1 points -1.1 to 0.5 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Creatinine | 52 of 1,514 18 of 579 | 0.3 points -1.6 to 1.9 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: Creatinine Kinase | 49 of 1,514 6 of 579 | 2.2 points 0.8 to 3.4 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Clinical Chemistry: γ-Glutamyl-transferase (GGT) | 54 of 1,514 14 of 579 | 1.1 points -0.6 to 2.6 | 2,093 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Haematology: Red Blood Cell Count | 31 of 1,513 13 of 579 | -0.2 points -1.9 to 1.1 | 2,092 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Haematology: Haematocrit | 48 of 1,513 22 of 579 | -0.6 points -2.7 to 1.0 | 2,092 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Haematology: Haemoglobin | 63 of 1,513 31 of 579 | -1.2 points -3.5 to 0.7 | 2,092 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
| OsmoPrep Tablets vs HalfLytely and Bisacodyl Tablet: serious adverse events | 20 of 1,041 19 of 1,051 | 0.1 points -1.1 to 1.3 | 2,092 | NCT01427296 Safety and Efficacy of OsmoPrep® Tablets Versus HalfLytely® and Bisacodyl Tablet Bowel Prep Kit for Colon Cleansing |
| Old Lina vs New Lina: Number of Patients With Abnormalities in Haematology: Eosinophils | 91 of 1,512 33 of 579 | 0.3 points -2.1 to 2.4 | 2,091 | NCT00736099 Safety and Efficacy of Linagliptin (BI 1356) as Monotherapy or in Combination in Type 2 DM |
Code
curl "https://conductscience.org/api/comparisons/v1?page=168"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=168
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT04498832-7114cff6",
"title": "QIV-HD vs QIV-SD: Number of Participants Reporting Serious Adverse Events (SAEs)",
"summary": "2 of 1049 against 5 of 1051; risk difference -0.3 points, 95% interval -0.9 to 0.3; NCT04498832, Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older",
"record": "/library/comparisons/NCT04498832-7114cff6",
"nct_id": "NCT04498832",
"kind": "outcome",
"participants": 2100,
"risk_difference": {
"value": -0.0028507962365498744,
"lower": -0.009330958749956448,
"upper": 0.0028589972677190755
},
"group_1": "2 of 1,049",
"group_2": "5 of 1,051",
"difference": "-0.3 points",
"interval": "-0.9 to 0.3",
"trial_title": "Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older"
},
{
"id": "NCT04498832-sae",
"title": "QIV-HD vs QIV-SD: serious adverse events",
"summary": "2 of 1049 against 5 of 1051; risk difference -0.3 points, 95% interval -0.9 to 0.3; NCT04498832, Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older",
"record": "/library/comparisons/NCT04498832-sae",
"nct_id": "NCT04498832",
"kind": "serious-adverse-events",
"participants": 2100,
"risk_difference": {
"value": -0.0028507962365498744,
"lower": -0.009330958749956448,
"upper": 0.0028589972677190755
},
"group_1": "2 of 1,049",
"group_2": "5 of 1,051",
"difference": "-0.3 points",
"interval": "-0.9 to 0.3",
"trial_title": "Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Japanese Adults 60 Years of Age and Older"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=169",
"request_id": "X5i_ljvz83xTPff8"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant